drugset / Trial / NCT06507306

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06507306

Phase 1 Recruiting 100 enrolled Kumquat Biosciences Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

Timeline

Start
2024-06-03
Primary completion
2026-07-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amivantamab Monoclonal antibody Subcutaneous
Subject KQB198 Unknown Oral
Subject Osimertinib Small molecule Oral

Indications